Homocysteineisariskfactor forcardiovascular disease and venous thrombosis.Clinical guidelinesd iffer in their recommendation whetherornot to measurehomocysteineafter methionine loading.Inthis study,weinvestigatedthe addedvalueofthe methionine loading test next to fasting homocysteine levels for identifying subjects at risk forv enous thrombosis or cardiovasculardisease,using ReceiverOperating Characteristic (ROC) curves.Theanalysis wasperformedin185 patients withr ecurrent venous thrombosis,130 patients withc ardiovascular disease and601 controls.Thediscriminatorypower of thefasting homocysteine measurementa lone fori dentifying subjects at risk of venous thrombosis expressedasthe area under the ROC curve (AUC) was 0.61(95%CI 0.56-0.66). Using bothafasting
Introduction
Hyperhomocysteinemia is ar isk factor forv enous thrombosis and cardiovasculard isease ( 1, 2) . Clinical guidelines differi n their recommendation whether or nottomeasurehomocysteine after methionine loading, next to measuring the fasting concentration. Most of these guidelinesrecommend not to use the methionine loading test in routine clinical settings, becausethe test is cumbersome and thereisinsufficient evidenceonthe association betweenpostload hyperhomocysteinemia and risk of vascular disease (3) (4) (5) (6) . However, some people advocatethe use of the methionine loading test, because without amethionine loading test 27% to 55% of subjectswith hyperhomocysteinemia will be missed (7) (8) (9) (10) .
The methionine loading test wasfirst usedfor the detection of subjects heterozygous for cystathionine β -synthase( CBS) deficiency (11) , whooften had hyperhomocysteinemia after methionine loading. Methionine loading wasusedinthose days to increase homocysteine concentrations, since basalh omocysteine levels could not be accuratelymeasured with the laboratory techniquesofthat time.
The observation thats ubjects with homocystinuria often sufferfrom severe cardiovascular diseaseand venous thrombosis leadt ot he hypothesis that mildh yperhomocysteinemia could also be associated with vasculardisease (12) . In 1976, Wilckenet al.(13) provided the first evidencethat hyperhomocysteinemia after methionine loading wasassociatedwith cardiovasculardisease. Thefirst studieso nh yperhomocysteinemia and cardiov-ascular disease suggested that study participants with postload hyperhomocysteinemia were heterozygousf or cystathionine β -synthased eficiency. Later,i tw as establishedt hat heterozygosityfor cystathionine β -synthasedeficiencyisnot, or onlya minor causeofpostload hyperhomocysteinemia (14) .
In the 80s,the development of moresensitive and precise laboratorytechniquesmade it possible to accuratelymeasurefasting homocysteine levels. From then on, both measurement methods, i.e. fasting homocysteine measurement and after methionine loading,w ere appliedi ne pidemiologicals tudieso nh yperhomocysteinemia and vasculardisease, yielding similar risk estimates ( 1, 9, 10, (15) (16) (17) (18) . This has initiated the discussion whether or nottoperform amethionine loading test in vascular disease, whichhas been obscured by the argument thatsubjects with isolatedp ostload hyperhomocysteinemia will remain undiagnosedwhen this test is omitted (7) (8) (9) (10) .
In ouro pinion, the real question is whether the methionine loading test increases the risk prediction for venous thrombosis or cardiovasculardisease. Forthat reason the addedvalue of the methionine loading test should be determinedb yi ts ability to identifysubjects at risk for venous thrombosis or cardiovascular disease. Most studies that assess the addedvalue of the methionine loading test, use risk estimatesfor homocysteine levels above ac ertain cut-off point (either fasting or after methionine loading).Results therefore largelydependonthe cut-offpoint that is chosen. In this study we trytoclarify the discussionusing ReceiverO perating Characteristic (ROC) curves, becauseR OC curvese nable us to assess the addedv alue of the methionine loading test over awhole range of homocysteine values. We performedthe analysesin185 patients with recurrent venous thrombosis, 130 patients with cardiovasculardiseaseand 601 control subjects.
Materials andmethods

Subjects
Forassessing the value of methionine loading in identifying subjectsa tr isk for venous thrombosis and cardiovasculard isease, we used the following study populations, whichare described in detail elsewhere (16, 18, 19) . We recruited185 patients whohad had twoormore episodesofvenous thrombosis throughananticoagulant clinic in The Hague (this group is further referred to as 'patients with venous thrombosis') (16, 18) . 130 patients with coronaryarterydiseasewhererecruitedthrough the Zuiderziekenhuis Hospital in Rotterdam, The Netherlands (19) .Theyhad had acoronary angiographyand had ≥ 90% occlusion in one and ≥ 40% occlusion in anothera dditional major coronarya rtery (thisgroupisfurther referred to as 'patients with cardiovascular disease'). As ac ontrol group, we used 500 control subjects recruited through ageneral practiceinThe Hague (16, 18) and 101 control subjects recruited from the generalp opulation in Rotterdam (19) .
Forboth the study on venous thrombosis and cardiovascular disease, the medicalethicscommittee approved the studyprotocol and informedc onsent waso btained from all study participants.
Methods
From all study participants, venous blood samples for total homocysteine determination where collected after an overnight fast. Hereafter,p articipants receiveda no ral methionine load consisting out of as ingle doseo f0 .1g L-methionine per kilogram of bodyweight. Six hours after the oral methionine loada secondblood sample wasobtained. In between, participants receivedonlyalow-protein meal (20) .Total homocysteine concentrations (fasting and postload) were determinedinEDTAplasma throughthe use of high-performanceliquid chromatographyand fluorescence detection (21) .All determinations where performed at the Radboud University NijmegenM edical Centre, The Netherlands.
Statisticalanalysis
Fasting and postload hyperhomocysteinemia wasd efineda sa homocysteine concentration above the 90 th percentilev alue of the distribution of the control group. 'Delta'homocysteine levels were defineda st he postload minus the fasting homocysteine concentration.
ROCc urvesw ere establishedf or the fasting homocysteine measurement alone, the postloadh omocysteine measurement alone,and for the twomeasurementscombined. We used logistic regression analysis to find the optimal combination of both measurements. To comparet he overallp rognostic value of the fasting and the postloadhomocysteine levels, we used the area under the curve (AUC).
Although ROC-curvesare notwidely used in the analysis of case-controld ata, theyp rovide ag ood insight in the additive value of acertain measurement (22) .Itshould be clear that they should not be interpreted as diagnostic ROC-curves(i.e.w edo not meant hat homocysteine is ad iagnostic tool to diagnose thrombosis or myocardialinfarction (likeD-dimers or troponine measurements). Theyshould be interpreted as prognosticROCcurves. As in case-controlstudies, we assume thatthe exposure measurement (homocysteine) is not affectedbythe disease (23) .
Results
The group characteristics areg iven in Table1 .F or the venous thrombosis group the age wash igherc ompared to the control group, while the cardiovascularpatients showedahigherpercentage of males.
Number of hyperhomocysteinemic subjects identified by fastingand/orpostload homocysteinemeasurement
The 90 th percentilevalue in control subjectswas 18.3 µ mol/L for fasting homocysteine levels and 59.5 µ mol/L for postloadhomocysteine concentrations.
We identified1 73 (59 venous thrombosis patients, 21 cardiovascularpatients and 93 controls) subjectswith hyperhomocysteinemia (fasting, postloado rb oth) of which1 14 (66%) could be diagnosedb ym easuring onlyf asting homocysteine levels ( Fig. 1, Table2 ). Theadditional 59 (20 venous thrombosis patients, 6cardiovascularpatients and 33 controls) hyperhomocysteinemics hadnormal fasting homocysteine levels and elevated postload homocysteine concentrations,i.e. theyhad isolated postload hyperhomocysteinemia. This implies that without a methionine loading test 33% (59 out of 173) of hyperhomocysteinemic subjects in this study would not be detected.
Receiver Operating Characteristic (ROC)curves
Becausethe purpose of the methionine loading test is not to diagnose hyperhomocysteinemia, buttoidentify subjects at risk for thrombosis,w eusedR OC-curve analysis to comparethe prognosticv alue of fasting and post-loadh omocysteine concentrations.F igure2s hows the ROC-curvesf or fasting and postloadhomocysteine concentrations and for the combination in the venous thrombosis group. We found thatt he area under the curvesw ere quite similarfor the fasting homocysteine (AUC= 0. As is shown in table1 ,t he venous thrombosis group was older than the control group while the cardiovascularp atient group showah igherp ercentage of males. Therefore we did a subgroup analysis in malesonlyand in asubgroup with asimlar age distribution. Also in these subgroup analyses,therewas no indication for an added value of the methionine loading test (data not shown).
"Deltah yperhomocysteinemia"
Instead of absolutep ostload homocysteine levels for detecting hyperhomocysteinemia one could also use "delta" homocysteine levels, i.e.the difference betweenfasting and postload homocysteine levels. Forthat reason, we also generated ROCcurvestoinvestigatethe addedvalue of determining delta homocysteine levels next to measuring onlyfasting homocysteine levels (Figures  nots hown) .The AUCf or delta homocysteine levels alonew as 0.62 [95%CI 0.57-0.66]), whichisthe same as the AUCfor absolutepostload homocysteine levels alone(AUC=0.64 [95%CI 0.59-0.69]),indicating that both methods areequallycapable of identifying subjectsa tr isk of venous thrombosis.T he combination of fasting homocysteine measurement and delta homocysteine levels together, yielded an AUCo f0 .66 (95%CI 0.60-0.69), whichmeans thatcalculating "delta"homocysteine levels after methionine loading hasnoadded value in risk assessment for venous thrombosis.Also in the cardiovascularpatient group therewas no added value of calculating "delta"homocysteine levels (datanot shown).
Discussion
We assessedthe addedvalue of the methionine loading test next to fasting homocysteine levels in risk assessment of venous thrombosis and cardiovasculardiseasebyusing ROCcurves. We showedthat the methionine loading test has no additional value as aprognostic tool for risk assessment of venous thrombosis or cardiovasculardisease.
Most guidelines do not recommend the use of the methionine loading test in ar outine clinicals etting becauset herei sn ot enough evidenceo nt he association betweenp ostload hyperhomocysteinemia and vasculardisease (3) (4) (5) (6) . Other drawbacks arethat this test is more expensive,isinconvenient for the patient and for the laboratoryand that the dose of methionine greatly exceeds the dailyintakeofmethionine (24).
However, an argument thatisoften used in favour of the methionine loading is that 27% to 55% of subjects with hyperhomocysteinemia will not be detected if amethionine loading test is omitted (7) (8) (9) (10) . Based on this result,people advocatethe use of the methionine loading test in all patients that arescreened for hyperhomocysteinemia or in asubset of these patients basedon the fasting homocysteine concentrations and thus lowering the totalamountofmethionine loading tests needed in clinical settings (25, 26) .
Although it is true that anormal fasting homocysteine level does not excludeaabnormal post-load homocysteine level, the purposeo fh omocysteine measurements is not to identify subjects with hyperhomocysteinemia, buttoidentify subjects at risk for venous thrombosis or cardiovasculardiseasethat maypossibly benefitfrom vitamin supplementation. Therefore, we evaluated the prognosticvalue of fasting and post-loadhomocysteine levels with ROC-curve analysis. Performing amethionine loading test in addition to afasting homocysteine measurement did not increase the AUCf or either venous thrombosis or cardiovasculard isease, indicating no added value of the methionine loading test. We have found thatt he fasting homocysteine measurement alonea nd the methionine loading test alone are moreo rl esse quallyc apable of identifying subjectsa tr isk for venous thrombosis and cardiovasculardisease. This means that clinicians can choosetoperform eitherafasting homocysteine measurement aloneo ram ethionine loading test alonei nr isk assessmentf or venous thrombosis and cardiovasculard isease. However, because fasting homocysteine measurementsa re cheaper,more feasible, and less invasive for the patient, fasting homocysteine measurement will be preferred.
We also investigated the added value of "delta"h omocysteine determination next to fasting homocysteine levels, which wasn il for both risk assessment of venous thrombosis and cardiovasculardisease. We choosetofocus on absolute postload homocysteine levels in this papero na ccount of the paperb y Ubbink et al. (27) , stating that postload homocysteine levels should not be adjustedfor fasting homocysteine levels becauseit results in an increased regression dilution due to higheranalyticaland biologicalvariability.
Our evaluation of the methionine loading test wasperformed on homocysteine samplesthat were drawn 6hours after the methionine load. Whether our resultsare alsoapplicable to homocysteine samples drawna ta nother time-intervali su ncertain. However, although time intervalsf or postload homocysteine measurement differ, most studiesm easurep ostload homocysteine levels eithera fter 4o r6h ours, and therei sahigh correlation between homocysteine samplesdrawn after ashorttime interval (2 or 3hours) and those drawn after 4to6hours (28, 29) . So, it is very unlikelythat other versionsofthe loading test will give moreinformation next to fasting homocysteine levels. We also would liket op oint out that our study wasr estrictedt o venous thrombosis and cardiovasculardisease. It does notapply to the value of methionine loading in assessmentofothermedical conditions,for instancecobalamin or folate deficiency, Alzheimer disease, vasculardementia,complications of pregnancy or neural tube defects (3).
Finally, it can be questionedw hetherh omocysteine levels should be measured at alli nc linical settings. Even if clinical trials showabeneficialeffect of vitamin Bsupplementation, it is not likelyt hat this effect is restricted to subjects with elevated homocysteine levels. Becauset herei saquite linear concentration-risk relationshipbetween homocysteine levels and vascular disease ( 30) , it is to be expected that, if therei sa ny effect, everysubjectmay benefitfrom vitamin supplementation independent from the initial pre-treatment homocysteine value.
In conclusion,the methionine loading test has no addedvalue next to fasting homocysteine measurement in identifying subjectsatrisk for venous thrombosis or cardiovasculardiseaseand for that reason should not be used in clinicalpractice.
